Max Robotics — Global Service Robot Directory + US Certification

About

Catherine M. Tangen is a leading biostatistician and epidemiologist whose research has profoundly shaped the management of prostate cancer. As a key figure in the Southwest Oncology Group (SWOG), her work centers on the design and analysis of large-scale clinical trials, with a major focus on urologic oncology. Her most impactful contribution is co-authoring the 2007 "Guideline for the Management of Clinically Localized Prostate Cancer," a seminal paper with over 1,100 citations that has served as a cornerstone for clinical decision-making worldwide. Tangen’s research has also provided critical insights into the natural history of the disease, including the landmark study "Impact of Previous Local Treatment for Prostate Cancer on Subsequent Metastatic Disease" (105 citations), which clarified long-term outcomes after primary therapy. Additionally, her work on neoadjuvant therapy for high-risk prostate cancer (62 citations) helped establish treatment paradigms for locally advanced disease. Through her rigorous statistical leadership, Tangen has enabled the urology community to move from anecdotal evidence to data-driven, evidence-based practice, making her an indispensable contributor to the fight against prostate cancer.